The historical rank and industry rank for Divi's Laboratories's PB Ratio or its related term are showing as below:
NSE:DIVISLAB'
s PB Ratio Range Over the Past 10 Years
Min: 5.81 Med: 9.28 Max: 14.36
Current: 10.7
During the past 13 years, Divi's Laboratories's highest PB Ratio was 14.36. The lowest was 5.81. And the median was 9.28.
NSE:DIVISLAB's PB Ratio is ranked worse than 93.06% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.855
vs NSE:DIVISLAB: 10.70
During the past 12 months, Divi's Laboratories's average Book Value Per Share Growth Rate was 12.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 9.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 11.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 14.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Divi's Laboratories was 53.50% per year. The lowest was 8.50% per year. And the median was 18.45% per year.
Back to Basics: PB Ratio
Divi's Laboratories (NSE:DIVISLAB) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Divi's Laboratories PB Ratio Related Terms
Divi's Laboratories PB Ratio Historical Data
* Premium members only.
The historical data trend for Divi's Laboratories's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Divi's Laboratories's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Divi's Laboratories PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Divi's Laboratories's PB Ratio distribution charts can be found below:
* The bar in red indicates where Divi's Laboratories's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Divi's Laboratories (NSE:DIVISLAB) has a PB Ratio of 10.70 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Divi's Laboratories and its competitors. This is 15% above median its historical median of 9.28. Over the past decade, Divi's Laboratories' PB Ratio has ranged from 5.81 to 14.36. According to the industry distribution chart, Divi's Laboratories ranks #858 out of 922 companies in the Drug Manufacturers industry, placing it in the top 93.1%.
Is Divi's Laboratories' PB Ratio too high?
Divi's Laboratories' current PB Ratio of 10.70 is 15% above median its 10-year median of 9.28. Over the past 10 years, this metric has ranged from a low of 5.81 to a high of 14.36. The Drug Manufacturers industry median PB Ratio is 1.86. Divi's Laboratories' value of 10.70 is 476.8% above this industry median. Based on the distribution chart, Divi's Laboratories ranks #858 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Divi's Laboratories has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Divi's Laboratories' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Divi's Laboratories ranks #858 out of 922 companies for PB Ratio. This places Divi's Laboratories in the lower half of its industry. The industry median PB Ratio is 1.86. Divi's Laboratories' value of 10.70 is 476.8% above this benchmark. Historically, Divi's Laboratories' own PB Ratio has ranged from 5.81 to 14.36 over the past decade. While the company's 10-year median is 9.28 vs. the industry median of 1.86, Divi's Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Divi's Laboratories's current PB Ratio of 10.70 is 476.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Divi's Laboratories and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Divi's Laboratories's current PB Ratio is 10.70, which is 15% above median its own 10-year median of 9.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Divi's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Divi's Laboratories (NSE:DIVISLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹6,729.63, compared to a current price of ₹6,753.50 — trading 0.4% above its estimated fair value. The current PB Ratio is 10.70, which is 15% above median its 10-year median of 9.28 and 476.8% above the Drug Manufacturers industry median of 1.86. Divi's Laboratories' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Divi's Laboratories (NSE:DIVISLAB), the current PB Ratio is 10.70 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Divi's Laboratories (NSE:DIVISLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Divi's Laboratories stock appears to be overvalued.
The current stock price of ₹6,753.50 is trading 0.4% above its estimated GF Value™ of ₹6,729.63.
GuruFocus considers Divi's Laboratories to be Fairly Valued.
Key valuation signals for NSE:DIVISLAB:
PB Ratio: 10.70 (15% above median its 10-year median of 9.28)
GF Value™: ₹6,729.63 vs. price of ₹6,753.50 (0.4% above fair value)
Industry Position: 476.8% above the Drug Manufacturers median (#858 of 922)
No single metric tells the full story. See the NSE:DIVISLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients, with a predominance in exports. It also, through its custom synthesis, supports pharma companies for their patented products business from gram-scale requirements for clinical trials to launch, as well as late-life cycle management. Geographically, the company derives maximum revenue from Europe, and the rest from America, India, Asia (excluding India), and the Rest of the world.
93GF Score
Get the complete analysis for NSE:DIVISLAB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:DIVISLAB has been successfully added to your 
